NCT01162031View on ClinicalTrials.gov

Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
LeukemiaAcute Lymphocytic Leukemia
Interventions
DRUG

Velcade

IV

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Stanford University

OTHER